Director/PDMR Shareholding
January 04, 2016 09:06 ET
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 3 January 2016, Pascal Soriot, a Director of the Company, notified us that,
on 31 December 2015, he ceased...
Result of External Audit Tender
December 23, 2015 11:30 ET
|
AstraZeneca PLC
Result of the External Audit Tender
AstraZeneca PLC (the Company) today announced a proposal to appoint
PricewaterhouseCoopers LLP (PwC) as its external auditor for the financial year
ending 31...
LESINURAD APPROVED BY US FDA FOR GOUT
December 23, 2015 02:01 ET
|
AstraZeneca PLC
ZURAMPIC® (LESINURAD) APPROVED BY US FDA
FOR PATIENTS WITH GOUT
AstraZeneca (http://www.astrazeneca-us.com/) today announced that the US Food
and Drug Administration (FDA) has approved...
TAGRISSO™ (OSIMERTINIB) POSITIVE CHMP OPINION
December 18, 2015 08:12 ET
|
AstraZeneca PLC
TAGRISSO™ (osimertinib) RECEIVES positive chmp OPINION FOR patients with EGFR
T790M mutation-positive METASTATIC non-small cell lung cancer
CHMP positive recommendation is based on an objective...
CHMP ISSUES POSITIVE OPINION ON LESINURAD FOR GOUT
December 18, 2015 08:03 ET
|
AstraZeneca PLC
CHMP ISSUES POSITIVE OPINION ON LESINURAD FOR GOUT
AstraZeneca today announced that the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
BRILIQUE (TICAGRELOR) POSITIVE EU CHMP OPINION
December 18, 2015 07:54 ET
|
AstraZeneca PLC
BRILIQUE (TICAGRELOR) RECEIVES POSITIVE EUROPEAN UNION CHMP OPINION FOR EXTENDED
TREATMENT OF PATIENTS with a history of heart attack
AstraZeneca today announced that the Committee for Medicinal...
ATLANTIC TRIAL SUPPORTS CLINICAL ACTIVITY
December 18, 2015 02:01 ET
|
AstraZeneca PLC
DURVALUMAB atlantic TRIAL supports clinical activity and ASTRAZENECA'S OVERALL
Immuno-Oncology Strategy
Durvalumab demonstrated clinical activity and durable responses in 3rd-line or
later stage...
ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA
December 17, 2015 09:16 ET
|
AstraZeneca PLC
AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA
AstraZeneca announced today the successful completion of the tender offer for
all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the...
AZ INVESTS IN ACERTA PHARMA TO ENHANCE GROWTH
December 17, 2015 02:00 ET
|
AstraZeneca PLC
ASTRAZENECA ENHANCES LONG TERM GROWTH THROUGH ONCOLOGY INVESTMENT IN ACERTA
PHARMA
Transaction includes late-stage, potential best-in-class irreversible small
molecule BTK inhibitor,...
AZ ACQUISITION OF TAKEDA'S RESPIRATORY BUSINESS
December 16, 2015 02:31 ET
|
AstraZeneca PLC
ASTRAZENECA TO STRENGTHEN THERAPY AREA FRANCHISE THROUGH ACQUISITION OF TAKEDA'S
RESPIRATORY BUSINESS
Acquisition to include non-US rights to roflumilast and will be accretive to
2016 earnings,...